Baxter changes reportable segments to two: MPT and HST, effective Q2 2026

BAXTER INTERNATIONAL INC

Former Pharmaceuticals segment moved into Infusion Therapies & Platforms division of MPT.
Certain manufacturing facility sales previously in Other now reported in ITP division.
Corporate cost allocation updated: some shared expenses now remain unallocated.
Recast historical segment data for 2024, 2025, and Q1 2026 provided in Exhibit 99.1.
No impact on consolidated net income, EPS, total assets, or stockholders' equity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.